ArticleImmunity, inflammation and disease2026
Albiflorin Relieves Intervertebral Disc Degeneration Through Inhibiting Nucleus Pulposus Cell via the p38 MAPK/NF-κB Pathway.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thrombospondin-4 Regulates Lipopolysaccharide-Induced Apoptosis and Inflammation in Nucleus Pulposus Cells via the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway.Immunity, inflammation and disease · 2026Article
- Albiflorin Relieves Intervertebral Disc Degeneration Through Inhibiting Nucleus Pulposus Cell via the p38 MAPK/NF-κB Pathway.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a chronic musculoskeletal disorder, intervertebral disc degeneration (IDD) is a leading cause of low back pain. Inflammatory response plays a key role in the IDD progression. Albiflorin (AF), a bioactive compound derived from Paeonia lactiflora, exhibits anti-inflammatory effects in various diseases. However, the effects of AF on IDD remain unexplored. This study explored the protective effect of AF against IDD and elucidate its possible mechanisms.
methodsNucleus pulposus (NP) cells were stimulated with lipopolysaccharide (LPS ) for 24 h to establish the IDD cell model, followed by AF or p38MAPK agonist (P79350) treatment. Cell viability and apoptosis were evaluated using 5-ethynyl-2'-deoxyuridine (EdU) assay and flow cytometry analysis, respectively. Levels of the Inflammatory cytokines (tumor necrosis factor alpha, TNF-α; interleukin-1beta, IL-1β; IL-6) were assessed by enzyme-linked immunosorbent assay (ELISA). The mRNA levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-Associated X (Bax), aggrecan, and collagen type II was analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), while their protein levels were determined by western blot assay.
resultsLPS induction remarkably inhibited NP cell proliferation (p < 0.001) and induced apoptosis (p < 0.001), which were significantly reversed by AF dose-dependently. Furthermore, AF treatment dose-dependently decreased extracellular matrix (ECM) degradation and inflammatory factors secretion in LPS-induced NP cells, evidenced by enhanced aggrecan and collagen type II protein expression (all p < 0.01), and reduced TNF-α, IL-1β, and IL-6 section (all p < 0.05). Mechanistically, AF exerted its protective effects by suppressing the p38 mitogen-activated protein kinase (MAPK)/nuclear factor κB (NF-κB) signaling pathway, as evidenced by reduced phosphorylation of p38 and p65 (all p < 0.01). Notably, co-treatment with P79350 partially abolished the protective effects of AF against LPS-induced NP cell damage.
conclusionAF relieved IDD through repressing NP cell apoptosis, inflammatory response, and ECM degradation through the p38 MAPK/NF-κB pathway, indicating that it is a potential IDD therapeutic agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.